Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Advances in the treatment of portal hypertension in cirrhosis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. An update on cirrhotic cardiomyopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Methotrexate for inflammatory bowel disease: time for reconsideration

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Glucagon like peptide-2 and neoplasia; a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. The role and advances of immunomodulator therapy for inflammatory bowel disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Non-selective beta-blockers and handling of esophageal varices has been key elements in the treatment of portal hypertension in recent decades. Liver vein catheterization has been essential in diagnosis and monitoring of portal hypertension, but ongoing needs for noninvasive tools has led to research in areas of both biomarkers, and transient elastography, which displays promising results in discerning clinically significant portal hypertension. Novel research into the areas of hepatic stellate cell function and the dynamic components of portal hypertension has revealed promising areas of treatment modalities, targeting intestinal decontamination, angiogenesis, inflammation and oxidative stress. Future studies may reveal if these initiatives lead to developments of new drugs for treatment of portal hypertension.

OriginalsprogEngelsk
TidsskriftExpert review of gastroenterology & hepatology
Vol/bind10
Udgave nummer8
Sider (fra-til)961-969
Antal sider9
ISSN1747-4124
DOI
StatusUdgivet - jul. 2016

ID: 46349076